30/10/2026
📄 New paper in Nature: “ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2”
🫁 Resectable non-small cell lung cancer (NSCLC) is associated with high risk of relapse despite perioperative treatment
💉 Phase 2 randomised platform trial of novel perioperative treatments for resectable NSCLC
🧬 Clearance of circulating tumour DNA (ctDNA) measured during neoadjuvant treatment was associated with longer event-free survival
🔬 Combined assessment of ctDNA clearance and pathological complete response status may improve risk stratification in NSCLC
🔗 https://doi.org/10.1038/s41586-026-11328-3